Abzena

Jul 22, 2025

Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

May 15, 2025

Abzena Announces Establishment of Scientific Advisory Board to Support Innovation Strategy

Feb 26, 2025

Abzena Strengthens Executive Leadership Team with the Appointment of Taylor Boyd as CBO

Jan 08, 2025

Abzena Strengthens Board with Appointment of Biopharma Industry Leader, Dr Moncef Slaoui

Nov 19, 2024

Abzena Expands Analytical Capabilities to Include GMP Cell-Based Potency Testing Across US & UK Sites

Oct 30, 2024

Abzena Announces Major Expansion in Microbiology Laboratory Space in Support of Biologic Manufacturing

Sep 26, 2024

AbZelectPRO(TM) enables biopharma customers to reach their research cell bank in 10 weeks with 8g/L

Aug 08, 2024

Abzena Supplies Clinical Trial Material for Angiex's Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC

Jun 20, 2024

Abzena and Argonaut Partner to Offer Accelerated End-to-End Drug Development Support for Biopharmaceutical Companies

Apr 25, 2024

Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Mar 27, 2024

Abzena Announces Major Investment in Bioconjugation and ADC Capabilities in Response to Increasing Industry Demand

Jul 28, 2020

Abzena Receives Growth Capital Investment from Newly Launched Biospring Partners